Press Releases

IR Mobile SiteTear sheetEmail pagePDF viewPrint viewRSS FeedsEmail AlertSocial Media Sharing


Year:
Notify me when new press releases are posted to this site.
Press Releases
3/09/2005Cubist Pharmaceuticals Names Michael Wood, M.D., and Martin Rosenberg, Ph.D., to Its Board of Directors
3/03/2005Cubist Pharmaceuticals to Purchase 2% Reduction in CUBICIN Royalty Rate from Lilly with Common Stock
2/23/2005Cubist Pharmaceuticals Announces Approval of Second Bulk Drug Manufacturing Facility; Plant will Provide Additional Production of Cubicin
2/22/2005Cubist Pharmaceuticals Announces Completion of Treatment Phase for All Patients in the Cubicin Endocarditis/Bacteremia Study; DMC Completes the Fifth Safety Review
2/21/2005Cubist Pharmaceuticals to Present at JMP Securities Fourth Annual Research Conference and Wells Fargo Securities Health Care Fireside Chats
2/15/2005Cubist Pharmaceuticals to Present at BIO CEO & Investor Conference; Michael W. Bonney will also Participate in Panel Discussion
1/25/2005Cubist Pharmaceuticals Reports Fourth Quarter and Full Year 2004 Results; Full Year Revenues Total $68.1 Million
1/10/2005Cubist Pharmaceuticals Announces Fourth Quarter 2004 Cubicin Revenues of $21.0 Million and Year-End 2004 Revenues of $58.6 Million
1/03/2005Cubist Pharmaceuticals to Announce Fourth Quarter 2004 Earnings on January 25th; Cubist to Present at JP Morgan Healthcare Conference
12/14/2004Cubist Pharmaceuticals Pays in Full $29 Million of Convertible Bond Debt
12/07/2004Cubist Pharmaceuticals to Present at Harris Nesbitt 2004 Healthcare Conference and First Albany Capital Annual Growth Conference
12/03/2004Newstream.com Digest: Online Shopping Safety Tips from `Mr. Modem', SanDisk Gadgets for Every Budget, Record-Setting Nirvana Box Set
12/02/2004Chiron and Cubist Pharmaceuticals Announce the Filing for EU Regulatory Approval to Market Cubicin -Daptomycin for Injection-
11/29/2004Cubist Pharmaceuticals Completes $120 Million Financing
11/23/2004Cubist Pharmaceuticals and XTL Biopharmaceuticals Announce Completion of Independent Data and Safety Monitoring Board Review of Phase 2 Data for HepeX-B
11/22/2004Cubist Pharmaceuticals Announces Pricing of 9,316,700 Shares of Common Stock
11/22/2004Zacks.com Features the Following Top Stocks in the Drugs Industry: Angiotech Pharma, Cubist Pharma, ImmunoGen, Johnson & Johnson, and QLT
11/17/2004Cubist Pharmaceuticals Announces Public Offering of 7.5 Million Shares of Common Stock
11/12/2004Cubist Pharmaceuticals Announces Chairman's Retirement
11/09/2004Cubist Pharmaceuticals Announces the Completion of Patient Enrollment in Cubicin's Phase 3 Endocarditis/Bacteremia Trial
 
 Source: SNL Financial LC 
Rows 281 through 300 of 407 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Copyright 2013, © SNL Financial LC  Terms of Use